Abstract
Lipid dysregulation within sebaceous glands is a critical factor underlying the pathogenesis of sebaceous gland disorders, particularly acne vulgaris. Sebaceous glands synthesize and secrete a complex mixture of lipids, including triglycerides, wax esters, free fatty acids, and sphingolipids, which contribute to skin barrier function and microbial homeostasis. Dysregulated lipid production, characterized by increased sebum secretion and altered lipid composition, has been implicated in promoting Cutibacterium acnes proliferation, hyperkeratinization, and inflammation, key processes in acne pathogenesis. Recent research highlights the pivotal role of sphingolipid metabolism, particularly ceramides, in modulating sebaceous gland activity and skin inflammation. Ceramide deficiencies in acne-prone skin contribute to compromised barrier integrity, increased microbial colonization, and an exaggerated inflammatory response. Furthermore, sphingolipid intermediates such as sphingosine-1-phosphate (S1P) influence sebocyte differentiation, lipid synthesis, and cytokine release, linking sphingolipid metabolism to sebaceous gland homeostasis. Emerging therapeutic strategies targeting sphingolipid pathways offer new opportunities for managing sebaceous gland disorders. Topical and systemic therapies designed to restore ceramide levels and modulate S1P signaling have shown promise in preclinical studies, with potential to reduce sebum production, enhance barrier function, and attenuate inflammation. Additionally, sphingolipid-targeted formulations combined with established treatments, such as retinoids and antimicrobial agents, may enhance therapeutic outcomes while minimizing side effects. The dysregulation of sebaceous lipid metabolism, particularly sphingolipid pathways, plays a central role in acne pathogenesis, and emerging insights into these mechanisms are shaping innovative strategies for the treatment and prevention of sebaceous gland disorders.